DAVID SIMM JOINS JDS THERAPEUTICS

DAVID SIMM JOINS JDS THERAPEUTICS

JDS Therapeutics, LLC Welcomes David Simm as Director of Marketing

PURCHASE, NY, June 1, 2012 – JDS Therapeutics, LLC, a marketer of proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals, announced today that David Simm has joined JDS Therapeutics as Director of Marketing. Mr. Simm will be responsible for planning and implementing various product launches for the Company.

Mr. Simm comes to JDS Therapeutics with over 25 years of healthcare marketing and sales experience in the pharmaceutical, reference laboratory, and hospital supply markets. He has launched five pharmaceutical drugs and 13 laboratory tests, and has been his company’s lead marketer on six co-promotions. Since beginning his pharmaceutical career at Lederle Laboratories, Mr. Simm has held director-level marketing positions at Daiichi Sankyo, Quest Diagnostics, and Roche, and has been responsible for product lines with annual revenues of $5 million to $850 million.  Prior to joining JDS Therapeutics, Mr. Simm was a healthcare consultant at CapitolMed, LLC, where he was involved in the launch planning and post-launch promotion of Gilenya® (fingolimod) from Novartis Pharmaceuticals Corporation, the first oral treatment for multiple sclerosis.

Mr. Simm holds a MBA, with majors in Marketing and Corporate Strategy, from The University of Michigan, and a BS in Economics, with majors in Marketing and Finance, from The University of Pennsylvania.

Commenting on the announcement, Michael Satow, President and CEO of JDS Therapeutics LLC, stated, “We are pleased to announce that David Simm has joined JDS Therapeutics as Director of Marketing. We are confident that David’s marketing and launch experience will be invaluable to JDS as we begin to commercialize our portfolio. David’s background and experience are well-suited to lead our marketing efforts during this exciting growth period of our young company.”

About JDS Therapeutics:
JDS Therapeutics markets proprietary, high-quality healthcare products to physicians, healthcare-delivery networks, and other healthcare professionals. JDS is focused on providing patients with scientifically backed, natural approaches to meeting their healthcare needs. JDS Therapeutics owns more than 100 issued patents worldwide involving clinically active natural compounds. JDS was founded in 2011, by Phillip and Michael Satow, a father and son team whose previous company, JDS Pharmaceuticals was sold in 2007 to Noven Pharmaceuticals for $125 million.

For more information, please contact us.